Open AccessA proteomic signature for dementia with Lewy bodies
Author(s) -
O'Bryant Sid E.,
Ferman Tanis J.,
Zhang Fan,
Hall James,
Pedraza Otto,
Wszolek Zbigniew K.,
Como Tori,
Julovich David,
Mattevada Sravan,
Johnson Leigh A.,
Edwards Melissa,
Hall James,
GraffRadford Neill R.
Publication year - 2019
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1016/j.dadm.2019.01.006
Subject(s) - dementia with lewy bodies , dementia , neurology , behavioral neurology , parkinson's disease , medicine , lewy body , disease , diagnostic accuracy , pathology , lewy body disease , psychiatry
We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease would distinguish patients with Lewy body disease from normal controls, and if it would distinguish dementia with Lewy bodies (DLB) from Parkinson's disease (PD). Methods Stored plasma samples were obtained from 145 patients (DLB n = 57, PD without dementia n = 32, normal controls n = 56) enrolled from patients seen in the Behavioral Neurology or Movement Disorders clinics at the Mayo Clinic, Florida. Proteomic assays were conducted and analyzed as per our previously published protocols. Results In the first step, the proteomic profile distinguished the DLB‐PD group from controls with a diagnostic accuracy of 0.97, sensitivity of 0.91, and specificity of 0.86. In the second step, the proteomic profile distinguished the DLB from PD groups with a diagnostic accuracy of 0.92, sensitivity of 0.94, and specificity of 0.88. Discussion These data provide evidence of the potential utility of a multitiered blood‐based proteomic screening method for detecting DLB and distinguishing DLB from PD.